Verso Biosense, based in Abingdon, has completed the first clinical study of its continuous uterine monitoring product and applied for UK regulatory approval
Usense, the first product developed by Verso Biosense, has successfully completed its first clinical study in partnership with the University of Southampton and National Institute for Health Research. Usense is a novel tool for better informing healthcare professionals when treating female infertility and was used to continuously monitor the uterine environment in 15 women over a 7-day period.
The device was well tolerated by all participants who received the implant, while the temperature and dissolved oxygen data collected provided a unique insight into a physiological environment that is critical for embryonic development. This environment has never been continuously monitored before and the unprecedented data was rich in detail, showing both variation between patients and variation over time.
Verso has made an application for regulatory approval for the Usense system with BSI for a UKCA mark and ISO13405 certification, this will shortly be followed by an application for a European CE mark.
Over the last five years Verso and the University of Southampton have filed eight patents across multiple territories to protect the system, implant and underlying technology.
Verso will now be looking to enter into formal commercial agreements with fertility clinics and clinicians within the UK and Europe to begin commercialisation of Usense.